Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $53,694.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,800 shares of Greenwich LifeSciences stock in a transaction dated Tuesday, January 13th. The stock was bought at an average price of $29.83 per share, for a total transaction of $53,694.00. Following the completion of the purchase, the chief executive officer owned 5,604,102 shares in the company, valued at $167,170,362.66. This represents a 0.03% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, January 12th, Snehal Patel acquired 2,900 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $27.54 per share, with a total value of $79,866.00.
• On Wednesday, December 31st, Snehal Patel purchased 4,300 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $21.36 per share, with a total value of $91,848.00.
• On Tuesday, December 30th, Snehal Patel acquired 2,900 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $21.73 per share, for a total transaction of $63,017.00.
• On Thursday, December 18th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $12.62 per share, for a total transaction of $51,742.00.
• On Tuesday, November 25th, Snehal Patel acquired 4,600 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $8.37 per share, with a total value of $38,502.00.
• On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.43 per share, with a total value of $89,358.00.
• On Friday, October 31st, Snehal Patel bought 2,300 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $9.26 per share, for a total transaction of $21,298.00.

Greenwich LifeSciences Stock Up 0.9%

Shares of Greenwich LifeSciences stock opened at $29.29 on Thursday. The stock has a market cap of $405.67 million, a price-to-earnings ratio of -20.06 and a beta of 1.47. Greenwich LifeSciences, Inc. has a twelve month low of $7.78 and a twelve month high of $32.91. The company’s fifty day moving average is $13.66 and its 200 day moving average is $11.83.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Friday, November 14th. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). As a group, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GLSI has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Wall Street Zen upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, HC Wainwright lifted their price objective on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $47.50.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of large investors have recently modified their holdings of GLSI. Citadel Advisors LLC increased its position in shares of Greenwich LifeSciences by 52.1% during the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock worth $208,000 after acquiring an additional 7,174 shares in the last quarter. Vanguard Group Inc. increased its holdings in Greenwich LifeSciences by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after purchasing an additional 13,179 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Greenwich LifeSciences in the second quarter worth approximately $509,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Greenwich LifeSciences in the second quarter valued at approximately $25,000. Finally, Geode Capital Management LLC boosted its position in shares of Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after buying an additional 1,972 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.